Nasdaq
$37.22▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.26BShares out 33.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
18- 5d agoPre-market26.10.20 07:14filedS-8Offering#●●●#●●●
NEKTAR THERAPEUTICS
Nektar Therapeutics has amended its 2025 Inducement Plan to increase the number of shares reserved for issuance by 250,000 shares. This Form S-8 registration statement covers these additional shares, bringing the total available for equity awards under the plan to 500,000 shares to be used as an inducement for new hires.…more
$37.22+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Pre-market26.10.01 20:578-KKey event
NEKTAR THERAPEUTICS
Nektar Therapeutics announced positive long-term data from its Phase 2b REZOLVE-AA clinical trial, showing that hair regrowth improvements were maintained and deepened for six months after 52 weeks of treatment with rezpegaldesleukin. The company also reported successful maintenance data from its Phase 2b REZOLVE-AD trial and confirmed plans to initiate a Phase 3 study for alopecia areata in early 2027.…more
$37.22+0.00%vs prev closeView filingShare - 9.28Pre-market26.09.28 20:51SCHEDULE 13G/AOwnership
NEKTAR THERAPEUTICS
Two Seas Capital LP has filed a SCHEDULE 13G/A statement regarding their beneficial ownership in Nektar Therapeutics. The filing serves as an update to the reporting entity's equity position in the company.…more
$37.22+0.00%vs prev closeView filingShare
17 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.1Pre-market26.10.01 20:33#●●●#●●●
Nektar Therapeutics Presents Phase 2b Data
Nektar Therapeutics presented long-term data from its Phase 2b clinical trials for rezpegaldesleukin at the EADV Congress. As the announcement lacks specific efficacy metrics or regulatory milestones, the market impact remains neutral.…more
$37.22+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.25Regular26.09.25 23:42
●●●●●●●● ●●●●● ●●●●●●
A federal jury found that Eli Lilly breached its contractual good faith obligations to Nektar Therapeutics, resulting in a $90 million damages award. The verdict remains subject to potential post-trial proceedings and appeals.…more
$37.22+0.00%vs prev closeShareBenzinga - 9.25Pre-market26.09.25 20:10
●●●●●●●● ●●●●● ●●●●●●
A jury found that Eli Lilly breached its license agreement with Nektar Therapeutics, awarding the company $90 million in damages. The verdict remains subject to post-trial proceedings and potential appeals.…more
$37.22+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report